- This event has passed.
New Technologies To Maximize Surgical Outcomes
March 18, 2021 @ 7:30 pm - 9:00 pm
New Technologies To Maximize Surgical Outcomes
-
WHEN
Thursday, March 18
7:30 - 9:00PM -
WHERE
ZOOM
-
REQUIREMENTS
MEMBERS ONLY
Join Surgical Field Product Specialist, Yeabsera Tamire, who will be presenting the Surgical and Sports Medicine Portfolio focusing on Foot and Ankle applications.
Products to be discussed are as follows:
- NuCel- Cryopreserved Amniotic Suspension Allograft for OR Site of Service
- Renu- Cryopreserved Amniotic Suspension Allograft for Private Office Site of Service
- Nushield- Complete Dehydrated Placental Allograft for OR, Private Office and Ambulatory Surgical Sites of Service
- FiberOS- Blend of demineralized cortical fibers, mineralized cortical powder, and demineralized cortical powder, all derived from the same donor, with natural osteoconductive and osteoinductive properties.
- OCMP- Blend of ground cancellous chips and demineralized cortical powder, derived from the same donor, with natural osteoconductive and osteoinductive properties
- Puraply AM- Collagen and PHMB Antimicrobial indicated for the management of surgical wounds
- Puraforce Tendon Reinforcement Matrix- Native Porcine ECM used to add support and reinforcement to tendon and soft tissue repairs
MEET OUR SPEAKERS
Yeabsera Tamire is a Field Product Specialist with Organogenesis. She has a degree in Biochemistry and Molecular Biology from University of Maryland, Baltimore County. She is a published author, with 7 years of experience in the field of regenerative medicine. Currently, Yeabsera bridges the gap between scientists, physicians, and surgeons by engaging in roles that allow dissemination of preclinical and clinical research about novel, cutting-edge biologics and allograft solutions, with the aim to translate biomedical research to directly help
SPONSORED BY:
Organogenesis was founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT). Our long and successful history of empowering healing began with the introduction of Apligraf®, the first and still the only living cell-based product that is FDA approved to treat both diabetic foot ulcers and venous leg ulcers. In 2014, our product portfolio expanded to include Dermagraft®, an FDA-approved therapy for the treatment of diabetic foot ulcers. The launch of our PuraPly® product line in 2015 gave clinicians new options for wound management across a variety of acute and chronic wound types. The introduction of PuraPly® Antimicrobial as an advanced wound care product has also addressed the growing need to manage bioburden and prevent biofilm reformation. In 2017, Organogenesis acquired NuTech Medical, which further expanded our product portfolio and introduced additional solutions for the advanced wound care market and enabled us to enter the surgical and sports medicine markets in a meaningful way.
